This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2023.
Program Description
Relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) may be either indolent or aggressive, with challenges due to limited treatment options. Chimeric antigen receptor (CAR) T-cell therapy has improved disease management as the therapy uses a patient’s own T cells to identify and attack cancer cells. However, this process is involved, lengthy, and associated with several unique toxicities. This program will examine the efficacy data, patient selection, and administration processes for recently approved and investigational CAR T-cell therapies for NHL. As patient care teams become more familiar and comfortable with the unique characteristics and toxicities of CAR T-cell products, oncology pharmacists need to help develop protocols for outpatient administration of CAR T cells, including logistics for their administration and storage. Approaches for adverse effect management, operational best practices, REMS requirements, multidisciplinary coordination, and establishing effective CAR T-cell programs will also be presented.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 14, 2023
Expiration date: April 14, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze emerging clinical evidence for use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of various non-Hodgkin lymphomas
- Identify best practices for ensuring safe and effective outpatient administration of CAR T-cell products
- Explore strategies for the prevention of CAR T-cell‒associated toxicities in the outpatient setting
Craig W. Freyer, PharmD, BCOP
Clinical Pharmacy Specialist - Hematology/Oncology, Hematopoietic Cell Transplant, and Cellular Therapy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Katie S. Gatwood, PharmD, BCOP
Stem Cell Transplant & Cellular Therapy Clinical Pharmacist Specialist
Vanderbilt University Medical Center
Nashville, Tennessee
Shawn Griffin, PharmD, BCOP
Clinical Assistant Professor - Department of Clinical Pharmacy Practice
University of California, Irvine
Irvine, California
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-137-H01-P. The activity is available for CE credit through April 14, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Katie S. Gatwood PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Speaker: Jazz Pharmaceuticals, Sanofi, Kite Pharma; Consultant: Sanofi; Grant funding: AstraZeneca
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Craig Freyer, PharmD, BCOP; Shawn Griffin, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA, CHCP; Amy Morris, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms